1Head of the Intensive Care Unit of the Clinica Mexico, Head of the Respiratory Diseases Unit of the Clinica México and Assigned Physician of the Intensive Care Unit and Leader of the COVID Unit of the General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico
2Associate Researcher, Assistant Physician in the Intensive Care Unit of the Mexico Clinic and General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico
3Associate Researcher, General Physician, Assistant Physician in the Intensive Care Unit of the Mexico Clinic and General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico
4Associate Researcher, Internal Medicine, Assistant Physician in the Intensive Care Unit of Clinica Mexico, Mexico
5Associate Researcher, General Surgery, Advanced Laparoscopy, Medical Director Clínica México, Mexico
6HOHY PTE LTD, Singapore
Introduction: At the end of 2019, a new coronavirus (2019-nCoV) was identified as the cause of pneumonia in the city of Wuhan, in the province of Hubei, China. In February 2020, the WHO designated this disease as COVID 19 (Coronavirus Disease 2019) and its etiological agent was named as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). In Mexico until June 23, 2021 there were 2,487,172 confirmed cases, 434,533 suspected cases, with 231,184 deaths. Regarding the confirmed cases, 18.51% required hospitalization and 81.29% only isolation at home. In the city of Piedras Negras, Coahuila, 6,701 confirmed cases were reported with 424 deaths and 43 active cases; of these, 10.87% required hospitalization and 89.13% only isolation at home. The markers that have been related to an increase in disease severity and mortality are Pro-B natriuretic peptide, high sensitivity troponin I, creatine phosphokinase MB fraction, interleukin-6, D dimer, C-reactive protein, sequential organ failure assessment (SOFA), lactate dehydrogenase, alanine-amino transferase, aspartate-amino transferase, hypoalbuminemia, leukocytosis, neutrophilia, lymphopenia, procalcitonin.
Objective of the Study: E valuate the ability to predict mortality, in COVID 19 patients treated at the Respiratory Unit at Clinica México, of the SAPS 3, SOFA, qSOFA, PORT and 4C Mortality Score.
Methods: Prospective, observational, longitudinal study from April 8, 2020 to May 21, 2021, patients with COVID 19. Severity scales and demographic data were recorded in the first 24 hours of admission. The statistical analysis was correlation and calculation of AUC for mortality with p < 0.05. Informed consent was obtained.
Results: 58 patients were admitted to the study, age 51.05 years, male 74.1%. Hospital mortality was 20.7%. The cause of admission was classified as Threat of organic failure 53.45%, Invasive Mechanical Ventilation and/or non- invasive since admission 43.10%. The average days of stay was 11.12, the average hours of invasive mechanical ventilation were 141.39, the average hours of non-invasive mechanical ventilation were 50.79. The predictive capacity for mortality was statistically significant for the four scales SAPS3 AUC = 0.84, SOFA AUC = 0.99, qSOFA AUC = 0.89, PORT AUC = 0.73 and 4C Mortality Score AUC = 0.81.
Conclusion: The scales SAPS 3, SOFA, qSOFA, PORT and 4C Mortality Score are useful as tools for predicting mortality in Mexican COVID 19 patients. The use of these tools can improve the profiling of patients to better distribute care resources, which are limited in most centers in our country. It is necessary to evaluate these results in a larger cohort and in other units with different characteristics from ours.
Keywords: COVID19; Mexico; Mortality; Mechanical Ventilation; Pneumonia; Prognosis
Jose Ivan Rodriguez de Molina Serrano., et al. "SAPS 3, SOFA, QSOFA, PORT and 4C Mortality Score as Predictors of Mortality in Patients with COVID 19 in Mexico." EC Clinical and Medical Case Reports 7.8 (2024): 01-12.
© 2024 Jose Ivan Rodriguez de Molina Serrano., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.net